Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343976 · ClinicalTrials.gov registry record · Phase 2
Pegylated Interferon Lambda Treatment for COVID-19
A Phase 2 study, sponsored by Raymond Chung.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT04343976: Clinical Trial Phase 2 study, sponsored by Raymond Chung.
NCT04343976 is a Phase 2 study that was terminated before completion, run by Raymond Chung. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04343976, a Phase 2 study, was terminated before completion, sponsored by Raymond Chung.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.
Primary Outcome
Negative COVID PCR testing 7 days after first lambda dose
Interventions
- DRUG Pegylated interferon lambda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
Why NCT04343976 stopped before completion
NCT04343976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Pegylated interferon lambda is the first listed.
NCT04343976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04343976 about?
NCT04343976 is a clinical study titled "Pegylated Interferon Lambda Treatment for COVID-19". Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.
What is the current status of trial NCT04343976?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2020-06-22. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT04343976?
The interventions under investigation include: Pegylated interferon lambda (DRUG).
Who is sponsoring clinical trial NCT04343976?
This trial is sponsored by Raymond Chung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04343976's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy